
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc. has demonstrated considerable growth potential, as evidenced by its average selling price (ASP) rising to $441 per test, reflecting a year-over-year increase of 9.2% alongside a 16% increase in volume for the quarter. The company has posted a year-to-date revenue growth of 19%, fueled by balanced increases in ASP and testing volumes, contributing to a positive trend in operational performance. Additionally, Exagen's cash position improved to $35.7 million, supporting its ongoing efforts to enhance its commercial strategies and expand its market presence to 45 territories by the end of 2025.
Bears say
Exagen Inc's financial performance has exhibited concerning trends, particularly in its second and third quarter results, despite an initial revenue beat of $17.2 million. The company experienced a significant reduction in workforce, with a 42 full-time equivalent (FTE) headcount decrease, impacting its sales, research and development, and other functions, which raises concerns about its operational efficiency and strategic focus. Furthermore, the persistent GAAP EPS loss of -$0.21, coupled with an EBITDA loss of $1.9 million and inconsistent revenue recognition, contributes to a negative outlook for the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares